Key Highlights
- Total Revenue for the third quarter ended September 30, 2026 was USD 14.1 million, down about 1% from USD 14.3 million a year earlier, as system revenue fell to USD 1.5 million from USD 3.5 million.
- Recurring revenue rose 17% to USD 12.6 million and made up 89% of the quarter's sales, against 75% a year ago, while procedure Volume grew 12% to 52,545 procedures.
- The GAAP net loss was USD 4.7 million, or USD 0.38 a share, versus a loss of USD 3.7 million, or USD 0.31, as a USD 3.4 million non-cash Warrant charge replaced a gain.
- Adjusted EBITDA was positive USD 1.7 million against negative USD 0.3 million a year earlier, and cash and investments stood at USD 12.6 million, with a new USD 10 million revolving Credit line undrawn.
Recurring Revenue Carries a Quieter Third Quarter
LENSAR (NASDAQ:LNSR) filed its Quarterly Report and held its Earnings Call on November 10, 2026. Total revenue was USD 14.131 million, compared with USD 14.316 million in the third quarter of 2025. Product revenue fell to USD 10.7 million from USD 11.4 million. Management said the dip reflected lower Capital system sales against a strong prior-year comparison, with the third quarter normally the slowest of the year because of summer holidays and surgical scheduling. The company said it placed 10 ALLY systems in the quarter, taking the ALLY installed base to about 225, and ended September with 12 ALLY systems in backlog.
Gross Margin Reaches 58% While Warrants Swing the Bottom Line
The company makes the ALLY robotic cataract laser and the LENSAR laser system, and earns revenue from system sales and leases, per-procedure licenses and service. Management said gross margin was 58% in the quarter versus 42% a year earlier, helped by mix and lower service costs. Selling, general and administrative expense fell to USD 8.1 million from USD 12.0 million, mostly on lower costs tied to the terminated Alcon merger. The operating loss narrowed to USD 1.4 million from USD 7.6 million. The net loss still widened because the change in Fair Value of warrant liabilities was a USD 3.4 million expense, against a USD 3.7 million gain in the prior-year quarter. For nine months, GAAP Net Income was USD 35.1 million, mainly from warrant gains and a USD 10.0 million Merger deposit that the company kept.
Liquidity, the Salem Five Credit Line and Product Timing
Cash and cash equivalents were USD 12.6 million at September 30, 2026, compared with USD 18.0 million of cash and investments at year end. Management said cash burn for the quarter was USD 0.9 million, and the company secured a USD 10 million asset-based revolving credit Facility in August 2026 from Salem Five Cents Savings Bank, which matures in August 2028. No amount had been drawn at quarter end. The filing lists risks that include operating losses, capital needs, tariffs and possible Shareholder litigation linked to the merger termination. Management said new robotic docking features for ALLY are expected by the end of the first quarter of 2027.
Where Things Stand
Recurring revenue reached 89% of sales because system sales shrank while procedure revenue grew, not because total revenue improved. LENSAR (NASDAQ:LNSR) posted a 1% revenue decline, a larger GAAP net loss and a smaller operating loss, with adjusted EBITDA positive at USD 1.7 million. The filings give no guidance, consensus figures or share price reaction. Items to watch are system placements against the 12-unit backlog, procedure volume after seasonal softness, the planned robotic docking release and the covenant on 2026 adjusted EBITDA.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...